In this regard, clinical achievements in cancer therapy with checkpoint inhibitors (CPI) revealed blocking inhibitory immune checkpoint molecules such as CTLA-4 and human programmed cell death protein 1 (PD1) resulted in significant therapeutic approaches (10). This evidence concerns the gene CTLA4 and cancer.